PLATINOS / ETOPOSIDE .
*.- DURVALUMAB BY ASTRAZÉNECA : OVERALL SURVIVAL DE 12.9 MESES .
*.- ATEZOLIZUMAB BY ROCHE : OVERALL SURVIVAL DE 12,3 MESES .
*.-TORIPALIMAB ( Aprobado Ya en CHINA ）: CONSIGUE UNA OVERALL SURVIVAL DE 14,6 MESES .
*****************
***********
*******
.jpeg)
Clinical Combined PET/CT Radiomics Model Prediction of Benefit From PLATINUM-BASED CHEMOTHERAPY And CHEMORADIOTHERAPY In Patients With SMALL CELL LUNG CÁNCER .
.jpeg)
Objective
To develop and validate a clinical combined radiomics model for predicting the treatment response and long-term survival prognosis of small cell lung cancer (SCLC) patients receiving platinum-based chemotherapy, as well as survival outcomes following chemoradiotherapy .
Methods
A total of 98 SCLC patients treated with platinum-based first-line chemotherapy were included in this study. Five prediction models for assessing the short-term efficacy of platinum-based first-line chemotherapy were developed using a logistic regression algorithm. The performance of the models was assessed by calculating the area under the curve of the receiver operating characteristic curves. For predicting progression-free survival (PFS) and overall survival in the platinum-based chemotherapy group and the chemoradiotherapy group, the optimal cutoff value was determined using X-tile software. Kaplan–Meier survival curves were plotted, and the log-rank test was used to compare survival outcomes .
Results
Conclusion
The clinical combined PET/CT radiomics model can noninvasively and accurately predict the response to platinum-based treatments in SCLC as well as long-term survival prognosis, which can contribute to personalized treatment strategies and guide precision therapy for SCLC patients .
.jpeg)
.jpeg)
.jpeg)
